Landmark Trial Shows IMDELLTRA® and IMFINZI® Combination Cuts Death Risk by 58 Percent in First-Line Small Cell Lung CancerNearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled